<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106076</url>
  </required_header>
  <id_info>
    <org_study_id>UCART123_03</org_study_id>
    <nct_id>NCT04106076</nct_id>
  </id_info>
  <brief_title>Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia</brief_title>
  <official_title>Phase I, Open Label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of Multiple Infusions of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor) in Patients With Adverse Genetic Risk Acute Myeloid Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellectis S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cellectis S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open-label, dose escalation study of UCART123 administered intravenously
      to patients with newly diagnosed CD123 positive adverse genetic risk acute myeloid leukaemia
      (AML) defined in the ELN adverse genetic risk group (2017). The purpose of this study is to
      evaluate the safety and clinical activity of multiple infusions of UCART123 and to determine
      the Maximum Tolerated Dose (MTD).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The trial was discontinued due to sponsor's decision and not a consequence of any safety
    concern
  </why_stopped>
  <start_date type="Actual">July 11, 2019</start_date>
  <completion_date type="Actual">December 5, 2019</completion_date>
  <primary_completion_date type="Actual">December 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AE/SAE/DLT [Safety and Tolerability]</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence, nature, and severity of adverse events and serious adverse events (SAEs) throughout the study</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Myeloid Leukaemia</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Several tested doses of UCART123 until the Maximum Tolerated Dose (MTD) is identified.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UCART123</intervention_name>
    <description>Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor</description>
    <arm_group_label>Dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Patients newly diagnosed with CD123 positive adverse genetic risk acute myeloid
             leukaemia (AML) defined as per ELN guidelines (DÃ¶hner et al., 2017)

          -  Eastern Cooperative Oncology Group performance status of 0 or 1

          -  No prior gene or experimental cellular therapy

          -  No organ dysfunction that in the opinion of the investigator precludes intensive
             induction chemotherapy or cellular therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghulam Mufti, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kings college London NHS Foundation Trust</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukaemia</keyword>
  <keyword>Newly diagnosed AML</keyword>
  <keyword>ELN adverse genetic risk group</keyword>
  <keyword>Chimeric Antigen Receptor T-Cell (CAR-T) therapy</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Transcription Activator-Like Effector Nuclease (TALEN)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

